Integral Diagnostics Limited (ASX: IDX), a leading provider of medical imaging services across Australia and New Zealand, has announced details for its full-year FY26 results presentation. The company will release its financial results on the morning of Tuesday, 25 August 2026, followed immediately by a group investor conference call at 11:00am AEST. The announcement provides investors with registration details and dial-in information for both Australian and New Zealand participants seeking to hear directly from management about the company's performance and strategic direction.

Key Points

  • Integral Diagnostics Limited (ASX: IDX) operates as a leading provider of medical imaging services across Australia and New Zealand
  • The company will release its FY26 results on the morning of Tuesday, 25 August 2026
  • An investor conference call is scheduled for 11:00am AEST on the same day immediately following results release
  • Investors can register online via the provided link or dial in using conference ID 10056165 from Australia, New Zealand, or Auckland local numbers
  • IDX operates a unique medical leadership model staffed by leading radiologists and diagnostic imaging specialists across Australasia

IDX's Market Position in Australasian Medical Imaging Services

Integral Diagnostics Limited operates as a leading provider of medical imaging services across both Australia and New Zealand, positioning itself as a key player in the diagnostic healthcare sector. The company's business model centres on delivering diagnostic imaging services through a network of facilities and practitioners across the region. IDX distinguishes itself through employment of Australasia's leading radiologists and diagnostic imaging specialists, reflecting a commitment to high-quality clinical expertise.

The company's operational footprint spans two major markets in the Asia-Pacific region, providing medical imaging services to patients and healthcare providers in both jurisdictions. This geographic diversification offers exposure to two developed healthcare systems with strong demand for diagnostic services. IDX's positioning as a "leading provider" in this space suggests established market presence and competitive standing within the medical imaging sector. The announcement indicates the company views its clinical leadership and specialist roster as core competitive differentiators in delivering patient care and service quality.

IDX's Unique Medical Leadership Operating Model

A distinguishing feature of Integral Diagnostics' operational approach is its adoption of a unique medical leadership model. This model emphasizes physician leadership and involvement in business strategy, contrasting with conventional healthcare service delivery structures. By placing radiologists and diagnostic imaging specialists in leadership positions, IDX has structured its organisation to align medical expertise with business decision-making. The company positions this approach as ensuring quality patient care, service delivery, and access to diagnostic services across its network.

The medical leadership philosophy embedded in IDX's operations reflects contemporary trends in healthcare administration where clinical practitioners hold significant roles in organisational governance and strategy. This structure is intended to ensure that clinical considerations, patient outcomes, and service quality remain central to business operations rather than secondary to financial objectives. The company's stated principle that "good medicine is good business" encapsulates this philosophy, suggesting that IDX believes superior clinical outcomes and patient care drive sustainable business performance. This operational differentiator may be relevant to institutional investors evaluating management quality and organisational alignment in healthcare service providers.

FY26 Results Release Timing and Investor Access Details

Integral Diagnostics has confirmed that its full-year FY26 results will be released on the morning of Tuesday, 25 August 2026. This timing follows the conclusion of the company's financial year and allows for customary audit completion and regulatory filing processes. The company has structured the results announcement to be immediately followed by a group investor conference call, enabling investors and analysts to access management commentary and guidance directly following the financial results publication. This same-day format allows market participants to hear strategic context and management perspectives without delay.

The investor conference call is scheduled to commence at 11:00am AEST, providing a convenient timing for participants across Australian and New Zealand time zones. IDX has provided multiple access methods to accommodate varying preferences among investors and analysts. The company has established an online registration portal via a dedicated link for those preferring web-based participation, while traditional dial-in telephone access is also available. Conference ID 10056165 is required for telephone participants. The company has noted that dial-in participants may experience wait times during peak call periods, which is typical for large investor conference calls. By providing both online and telephone access, IDX is ensuring broad accessibility for its investor audience across different regions and technical capabilities.

Online Registration and Telephone Dial-In Access for Investors

Investors wishing to participate in the Integral Diagnostics investor conference call on 25 August 2026 have been provided with a dedicated online registration link: https://s1.c-conf.com/diamondpass/10056165-zch721.html. Online registration offers investors a streamlined method to secure access to the webcast component of the conference call and receive any supplementary materials or updates related to the presentation. This approach is standard practice in modern investor relations and allows the company to manage attendee information and provide follow-up communications to registered participants.

For investors preferring traditional telephone dial-in access, IDX has published dedicated telephone numbers for both Australian and New Zealand participants. Australian investors can dial 1800 809 971 (toll-free within Australia) or 02 9007 3187 (Sydney local number) to access the call. New Zealand investors have access to 0800 453 055 (toll-free within New Zealand) or +64 9 929 1687 (Auckland local number). All telephone participants must provide conference ID 10056165 to the operator to join the call. The company has cautioned that participants may experience wait times during call commencement, particularly given the volume of investor interest expected in a results conference call for a publicly listed company. This multi-method access approach reflects professional investor relations practice and ensures participation barriers are minimised for IDX's shareholder base.

Contact Information for Investors Requiring Additional Details

Integral Diagnostics has designated John Merity, the Company Secretary, as the primary contact for investors and stakeholders requiring further information regarding the FY26 results release and conference call logistics. Merity can be reached by telephone at 0418 817 255 or via email at [email protected]. The provision of a direct contact person with contact details enables investors to obtain clarification on registration processes, technical access issues, or any other logistical questions relating to the investor conference call. This personalised contact approach supports accessibility for investors who may encounter difficulties with online registration or require additional assistance.

The company's investor relations infrastructure includes its corporate website at www.integraldiagnostics.com.au, which serves as the primary information resource for announcements, financial reports, and corporate updates. IDX has established operational contact details through its head office located at Level 2, 288 Victoria Parade, East Melbourne, Victoria 3002, with postal correspondence directed to PO Box 551, East Melbourne, VIC 8002. A general enquiries email address ([email protected]) and telephone line (+61 3 5339 0704) are also available for broader stakeholder queries. This multi-channel communication approach ensures investors can access support through their preferred communication method and reach appropriate personnel within the organisation.

Significance of FY26 Results Presentation for Stakeholder Assessment

The release of Integral Diagnostics' FY26 financial results represents a critical disclosure moment for investors seeking to evaluate the company's financial performance, operational metrics, and strategic direction. Full-year results announcements typically include audited financial statements, management commentary on market conditions and operational performance, and forward-looking guidance where management considers it appropriate. For a medical imaging services company operating across multiple geographic markets, investors will be reviewing metrics such as revenue performance, utilisation rates of imaging facilities, pricing dynamics, staffing levels, and capital investments in imaging technology and facility expansion.

The investor conference call provides an opportunity for management to contextualise financial results within broader industry trends, including demand for diagnostic imaging services, competitive dynamics in the medical services sector, and strategic initiatives underway within IDX. Analysts covering the company will use this information to update financial models and investment theses. Institutional investors will assess whether recent performance aligns with previous guidance and internal projections. The timing of results release followed immediately by investor dialogue is intended to facilitate efficient market pricing of information and reduce information asymmetry between management and the investment community. This structured approach to results disclosure and investor communication is standard practice for ASX-listed companies and reflects regulatory requirements under ASX listing rules.

Future Financial Reporting and Investor Engagement Calendar

The announcement of IDX's FY26 results release date and conference call details serves as a key marker in the company's investor engagement calendar for 2026. Following the August results release, investors and analysts will typically look toward the company's next scheduled disclosure events, which may include interim FY27 results announcements, trading updates, capital management announcements, or strategic corporate developments. The standard ASX-listed company reporting cycle involves full-year results release (typically August or September for companies with June financial year ends), followed by interim results release in the subsequent February period, creating regular touchpoints for investor communication and information flow.

IDX's commitment to holding a dedicated investor conference call immediately following results release demonstrates a structured approach to investor relations and capital market engagement. This practice ensures that investors and analysts receive consistent, contemporaneous access to management commentary and strategic context. The availability of both online and telephone participation methods reflects modern investor preferences and accessibility standards. For investors monitoring IDX or considering investment in the company, the FY26 results presentation on 25 August 2026 will represent the primary source of audited financial information and management guidance regarding the company's FY26 operational and financial performance. Following this announcement, investors may anticipate further periodic disclosure consistent with ASX listing rules and regulatory requirements applicable to listed entities.

Healthcare Services Sector Dynamics and Diagnostic Imaging Demand

Integral Diagnostics operates within the healthcare services sector, specifically medical imaging and diagnostic services, which represents a critical component of modern healthcare delivery systems. Diagnostic imaging services including X-ray, CT scanning, MRI imaging, ultrasound, and related diagnostic procedures are fundamental to patient diagnosis, treatment planning, and medical management across both Australia and New Zealand. Demand for diagnostic imaging services is typically driven by factors including population growth, aging demographics, chronic disease prevalence, healthcare spending patterns, and clinical guidelines governing imaging utilisation across different patient populations and medical conditions.

The medical imaging sector in Australia and New Zealand operates within regulated healthcare environments with professional oversight by regulatory bodies, clinical colleges, and accreditation bodies governing imaging standards and radiologist qualifications. Both countries maintain sophisticated healthcare systems with significant private and public sector components. Diagnostic imaging services are provided through public hospitals, private imaging centres, and integrated healthcare networks, creating a diverse competitive landscape. IDX's positioning as a leading provider with a network spanning both countries positions the company to benefit from underlying demand for diagnostic services across multiple geographic markets and patient segments. Industry trends such as technological advancement in imaging modalities, increasing diagnostic complexity, and growing prevalence of chronic diseases supportive of ongoing demand for imaging services are relevant to assessing IDX's business trajectory and growth potential.